Endocrinology

Back to articles

STAR shines on raloxifene

KEY POINT

The Study of Tamoxifen and Raloxifene (STAR) has shown that while both drugs are effective in reducing the incidence of invasive breast cancer by 50% (17 cases or 2% per group), taking raloxifene (Evista—Lilly) 60 mg orally daily is associated with 36% fewer cases of uterine cancer (0.48% vs. 0.76%, P = 0.07), 29% less cases of thromboembolism (0.7% vs. 0.9%, P = 0.01), and a 21% lower rate of cataract development (3.2% vs. 4.1%, P = 0.002) than tamoxifen 20 mg orally daily.

SOURCES

Vogel VG et al. Effects of tamoxifen and raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. JAMA. 2006;295:2727–41.

Gradishar WJ, Cella D. Selective estrogen receptor modulators and prevention of breast cancer. JAMA. 2006;295:2785–6.

National Breast Cancer Coalition. The STAR trial: raloxifene versus tamoxifen for breast cancer risk reduction. 2006.